Rare diseases, exceptional people: Filippo Buccella has battled for 25 years to improve care for children with Duchenne Muscular Dystrophy (DMD ... Doctors offered little hope for his future ...

Columnist Shalom Lim shares how his business, Rebirth Ensemble, will allow him to pursue visual arts and support artists with disabilities.

Kuntz, MD, was a fellow about 45 years ago, there were few more devastating diagnoses than Duchenne muscular dystrophy (DMD).

Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51. The drug – formerly known as SRP-5051 ...

The EMBARK Phase 3 study for Elevidys, Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, was published this month in Nature Medicine. The paper largely reiterates what’s ...

VIJAYAWADA: Founded by Sobharani Sunkara in 2019, the Amaravathi Rare Diseases Organisation (ARDO) has emerged as a beacon of hope for individuals suffering from muscular dystrophy (MD ...

Opens in a new tab or window SAVANNAH, Ga. -- Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary endpoint but differences ...

Zinc supplementation showed limited benefits in improving muscle health and hydration in boys with DMD. Nearly 30% of participants had low zinc levels initially, with slight improvement post ...

Jefferies has initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT) at buy saying its Duchenne muscular dystrophy franchise represents a $4B+ opportunity, as well as a strong pipeline and ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Wave Life Sciences (NASDAQ:WVE) stands against other biggest ...